Alkem Laboratories reported a 15% year-on-year reduction in its Scope 1 and Scope 2 greenhouse gas emissions for the financial year ended March 31, 2026, marking significant progress toward its voluntary target of a 42% cut by FY 2033 from an FY 2023 baseline. The Mumbai-based pharmaceutical company also recorded a 22% decrease in overall energy consumption, with renewable sources accounting for approximately 27% of its total energy mix during the period.

The disclosure was made under Regulation 34(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, via its Business Responsibility and Sustainability Report (BRSR) for FY26. Deloitte Haskins & Sells LLP provided reasonable assurance on the core indicators of the report. The data reflects standalone operations, noting that the generic business undertaking was transferred to Alkem Wellness Limited effective October 1, 2025.

Environmental Performance

Total Scope 1 and Scope 2 emissions declined to 93,205 tCO2e in FY26, down from 1,09,097 tCO2e in FY25. Scope 1 emissions dropped sharply to 19,088.7 metric tonnes of CO2 equivalent, compared to 33,018 metric tonnes in the previous year. Scope 2 emissions (market-based) were recorded at 74,116.3 metric tonnes of CO2 equivalent, slightly lower than the 76,079 metric tonnes reported in FY25.

Energy efficiency initiatives included the installation of IoT-enabled meters for real-time monitoring and the use of bio-briquettes in boilers as an alternative to fossil fuels. The company achieved ISO 50001 certification across 100% of its operational units. Total energy consumption was 7,54,500 GJ, comprising 2,01,332 GJ from renewable sources and 5,53,168 GJ from non-renewable sources.

Waste and Water Management

Alkem recycled 4,376 metric tonnes of plastic packaging waste under its Extended Producer Responsibility (EPR) framework in FY26, up from 3,961 metric tonnes in FY25. The company recycled or reused 99% of its non-hazardous waste. Total waste generated was 6,228 metric tonnes, of which 5,151 metric tonnes were recycled and 780 metric tonnes underwent other recovery operations.

Water stewardship remains a key priority, with the company targeting water neutrality by FY 2030. Total water withdrawal decreased to 6,19,064 kilolitres from 6,84,761 kilolitres in FY25. Approximately 84% of treated wastewater was reused within facilities for utilities and landscaping. Zero Liquid Discharge systems are operational at 58% of manufacturing units.

Social and Governance Metrics

The company maintained a Lost Time Injury Frequency Rate (LTIFR) of 0.07 per one million person-hours worked for workers, down from 0.09 in FY25. No fatalities were reported. Employee well-being spending constituted 0.2% of total revenue, down from 0.3% in the previous year. Gender diversity in the total workforce stood at 3.39%, with women comprising 17% of the Board of Directors.

What the Numbers Show

The sharp decline in Scope 1 emissions (from 33,018 to 19,088.7 tCO2e) outpaced the reduction in total energy consumption, suggesting that fuel switching—specifically the adoption of bio-briquettes and cleaner fuels—was a more potent driver of decarbonization than pure efficiency gains during FY26. This structural shift in the energy mix aligns with the company’s stated strategy to increase the share of cleaner energy sources.

Alkem Laboratories will host a conference call on Friday, August 14, 2026, at 4:30 PM IST to discuss its Q1FY27 financial results. The event provides investors and analysts an opportunity to review the company’s performance for the quarter ending September 30, 2026, following the release of the official financial statements. This disclosure aligns with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency in corporate communications.

The conference call will be conducted by Motilal Oswal Securities Ltd., which will facilitate the interaction between the company’s leadership and the investment community. Alkem Laboratories’ management team will be represented by Sandeep Singh, Managing Director, and Nitin Agrawal, Chief Financial Officer. These executives are expected to address operational highlights, financial metrics, and strategic initiatives relevant to the quarter.

Conference Call Details

Participants can join the call via dial-in numbers provided for domestic and international attendees. The session is scheduled to last from 4:30 PM to 5:30 PM IST. Investors are advised to dial in 10 minutes prior to the start time to ensure seamless entry.

Access and Registration

For those preferring digital access, an Express Join option is available via the Diamond Pass registration link provided in the official intimation. This method allows participants to bypass initial waiting lines and join the conference directly. The registration process requires a confirmation number and security string, ensuring secure access for verified attendees.

Key Participants

The primary speakers for the session include:

• Sandeep Singh, Managing Director
• Nitin Agrawal, Chief Financial Officer

Tushar Manudhane, Institutional Research Analyst – Healthcare at Motilal Oswal Securities Ltd., will oversee the research aspect of the call. For further inquiries regarding investor relations or media coverage, Purvi Shah and Isha Trivedi from Alkem Laboratories’ Investor Relations department are available for contact.

What the Numbers Show

While specific financial figures are not detailed in this announcement, the scheduling of the call indicates that Alkem Laboratories has completed its audit and compliance processes for Q1FY27. The involvement of Motilal Oswal Securities Ltd. suggests a structured approach to disseminating information to institutional and retail investors alike. Market participants should monitor the subsequent release of the full earnings transcript for detailed insights into revenue trends, profit margins, and future guidance.